Drug Trial Radar · NCT01710631
Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia
Last checked: Nov 20, 2026Latest source record: Oct 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
791
Actual
Start
Feb 2001
Primary completion
Aug 2002
Study completion Aug 2002
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A six-month study to determine the safety and efficacy with an additional open-label extension to determine the long-term safety of eszopiclone in the treatment of adult subjects with primary insomnia.
Conditions
- Primary Insomnia
Interventions
eszopiclone 3 mgDrug
eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average sleep latency over the last half of the double-blind study period ("last-three-month average" = mean of the monthly averages for months 4, 5, and 6)Time frame: Months 4-6
- Occurrence of Adverse Events (AEs) to evaluate the safety of eszopicloneTime frame: 12 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.